Oberweis Asset Management Inc Vericel Corp Transaction History

Oberweis Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$8.5 - $15.82 $213,945 - $398,189	-25,170 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$7.25 - $19.22 $1.81 Million - $4.8 Million	-249,953 Reduced 90.85%	25,170 $231,000
Q4 2019 Feb 14, 2020	SELL	$13.77 - $19.2 $3.57 Million - $4.98 Million	-259,500 Reduced 48.54%	275,123 $4.79 Million
Q3 2019 Nov 14, 2019	BUY	$14.93 - $19.83 $443,316 - $588,812	29,693 Added 5.88%	534,623 $8.09 Million
Q2 2019 Aug 14, 2019	BUY	$15.01 - $18.89 $63,942 - $80,471	4,260 Added 0.85%	504,930 $9.54 Million
Q1 2019 May 15, 2019	BUY	$16.23 - $20.29 $1.9 Million - $2.37 Million	116,800 Added 30.43%	500,670 $8.77 Million
Q4 2018 Feb 14, 2019	BUY	$10.77 - $18.44 $3.11 Million - $5.33 Million	288,970 Added 304.5%	383,870 $6.68 Million
Q3 2018 Nov 14, 2018	SELL	$9.1 - $14.8 $360,360 - $586,080	-39,600 Reduced 29.44%	94,900 $1.34 Million
Q2 2018 Aug 14, 2018	BUY	$9.6 - $14.6 $390,720 - $594,220	40,700 Added 43.39%	134,500 $1.31 Million
Q1 2018 May 15, 2018	BUY	$5.7 - $12.3 $534,660 - $1.15 Million	93,800 New	93,800 $933,000

276

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.79B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oberweis Asset Management Inc with notifications on news.